Aclaris Therapeutics
ACRS
96 hedge funds and large institutions have $130M invested in Aclaris Therapeutics in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 29 increasing their positions, 29 reducing their positions, and 36 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 29
1.07% less ownership
Funds ownership: 85.9% → 84.84% (-1.1%)
9% less capital invested
Capital invested by funds: $144M → $130M (-$13.4M)
12% less funds holding
Funds holding: 109 → 96 (-13)
36% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 36
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.62M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.29M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.73M |
| 4 |
Morgan Stanley
New York
|
+$1.52M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$831K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.14M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.71M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.36M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.14M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$705K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CM
126
Capula Management
Grand Cayman,
Cayman Islands
| – | -$23.9K | -15,593 | Closed |
|
127
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$22K | -14,694 | Closed |
|
128
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$18.7K | -12,200 | Closed |
|
|
PCM
129
Prelude Capital Management
New York
| – | -$18K | -11,791 | Closed |
|
|
BHCM
130
Brevan Howard Capital Management
St. Helier,
Jersey
| – | -$17.4K | -11,373 | Closed |
|
|
PD
131
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$9.38K | -6,132 | Closed |
|
|
TRCT
132
Tower Research Capital (TRC)
New York
| – | -$5.15K | -3,413 | Closed |
|
ACRS Hedge Fund Activity: Q2 2025 in Review
96 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2025, worth a combined $130M — down 9.3% from $144M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ACRS and 23 opened new positions — a net loss of 13 holders — while 29 trimmed existing stakes and 29 added.
The largest buyer was BlackRock, adding an estimated $5.62M. The largest seller was RA Capital Management, exiting entirely with an estimated $7.14M sold.
- 96 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2025, down from 109 in Q1 2025.
- Funds reported $130M of Aclaris Therapeutics stock for Q2 2025, down 9.3% quarter-over-quarter.
- 23 funds opened new Aclaris Therapeutics positions in Q2 2025 and 36 closed out, a net change of -13 holders.
- The largest Aclaris Therapeutics buyer in Q2 2025 was BlackRock, an estimated $5.62M added.
- The largest Aclaris Therapeutics seller in Q2 2025 was RA Capital Management, an estimated $7.14M sold.
Based on aggregated 13F filings for Q2 2025.